Home
overview

CHRISTMAS SPECIAL AVAILABLE - Register by 15th December to save £500!

Analgesics are among the most commonly prescribed drugs in the world and yet, finding novel targets and mechanisms that may elevate hard to treat pain is becoming more difficult. After nearly 20 years of successful Pain Therapeutics conferences, join us for the 18th Annual Pain Therapeutics conference in May to explore novel targets for pain therapeutics, new translational approaches and pipeline drug development from the leading pharma companies in pain management.

 

With more case studies, improved networking opportunities and presentations on exciting cutting edge research, the 18th Annual Pain Therapeutics conference will equip you with the latest knowledge to advance your research and trials.

Benefits of attending:

  • Discover the novel targets for pain management and hear how leading pharma companies are utilising them to elevate pain across a range of pain types.
  • Learn from exciting case studies of analgesic drug development and trials.
  • Explore the mechanisms by which that latest drugs elevate pain.
  • Discuss the future of pain therapeutics and how big data and technology are shaping the industry..
  • Advance your research and trials with the latest advice from the regulatory bodies
  • Hear industry perspectives from leading pharamceutical companies 
     

The upcoming Pain Therapeutics conference moves away from well discussed topics such as opioid dependence and animal models and focuses on the most exciting current research, opinions, novel targets and mechanisms and advances in the field of analgesic medicine

Who Should attend:

Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:

  • Pain and Migraine
  • Inflammation
  • Chronic Pain
  • Neuropathic Pain
  • Analgesic pre-clinical development
  • Anaesthesia and Pain Management
  • CNS clinical trials
  • Ion Channel Pharmacology
  • Pharmacology Intelligence
  • Translational science
  • Drug development
  • Exploratory development

 

Past Attendees include:

AiCure; Amgen; Analgesia Partnership; Apollo Therapeutics; AstraZeneca; Bayer; Bayer AG; biogen; Cara Therapeutics ; Centre for Human Drug Research; Centrexion Therapeutics Corp.; Chdr; Clermont Universit; Convergence Pharmaceuticals; Daiichi Sankyo Co. Ltd.; Daiichi Sankyo co.ltd; Eli Lilly and Company; ENSCCF Sigma Clermont; Eupraxia Pharmaceuticals Inc; Family Cottage Sydney; GlaxoSmithKline; Grunenthal; Grunenthal GmbH; Gsk; Innopain; Ipsen Innovation; J & JPRD; Kings College London; Lucideon; MD Biosciences; Merck & Co.; MRC Technology; Mundipharma International Limited; Mundipharma International Ltd; Mundipharma Research; Mundipharma Research GmbH & Co. KG; Mundipharma Research Ltd; Nektar Therapeutics; NeuroDigm; Novartis; Pharmaleads; Premier Research; Queens University Belfast; Queen's University Belfast; Transpharmation Ltd; University of Manchester; US Army Institute for Surgical Research; Zoetis;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Joseph Stauffer

Joseph Stauffer, Chief Medical Officer, Cara Therapeutics
View Bio

9:10 Finding targets and using animal models appropriately for pain therapeutics

  • Translatability of preclinical evidence is debated in the pain field, but are there exceptions that prove (or disprove) the rule?
  • Alternatively, can we take an opportunistic approach and focus on targets with clinical evidence provided by serendipity?
  • This presentation will address these questions considering various examples.
  •  

    Jenny Laird

    Jenny Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    View Bio

    Lisa Broad

    Lisa Broad, Senior Research Advisor , Eli Lilly and Company
    View Bio

    9:50 Drug discovery approaches in neuropathic pain and migraine – apples and oranges or lemons and limes?

    Gordon Munro

    Gordon Munro, Senior Scientist, Danish Headache Centre
    View Bio

  • Therapeutics target distinct facets of disease pathophysiology in neuropathic pain and migraine
  • Shared neurobiological mechanisms in neuropathic pain and migraine
  • Limitations to drug development –animal models and/or patient populations
  • Harmonizing knowledge gained from neuropathic pain research and development with migraine drug discovery
     
  • 10:30 Morning Coffee

    11:00 Translational oppertunities and challenges in chronic pain

    Alexander Oksche

    Alexander Oksche, Executive Director , Mundipharma Research GmbH & Co. KG
    View Bio

  • Where are we in our understanding of chronic pain and about appropriate cellular targets?
  • How to bridge the translational gap from preclinical models to patient selection?
  • Will personalised medicine provide us with new avenues for mechanism-based treatments
  • Risk signatures and biomarkers – what are the opportunities and challenges in chronic pain?
     
  • 11:40 Pain vs Nociception: How appropriate is the use of animal models in pain therapeutics

  • Role of animal models in the failure of pain therapeutic development
  • How reliable are the surrogate markers for pain in animal models
  • What are the alternatives to animal models
  • Why do Pre-clinical trials still use animal models
     
  • Gordon Munro

    Gordon Munro, Senior Scientist, Danish Headache Centre
    View Bio

    Jenny Laird

    Jenny Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    View Bio

    Alexander Oksche

    Alexander Oksche, Executive Director , Mundipharma Research GmbH & Co. KG
    View Bio

    12:20 Networking Lunch

    13:20 KEYNOTE ADDRESS: Abdominoplasty as a Novel Analgesic Model for Acute Soft Tissue Pain

    Neil Singla

    Neil Singla, Founder & Chief Scientific Officer, Lotus Clinical Research, Llc
    View Bio

  • Abdominoplasty has been validated as an acute pain model with high assay sensitivity
  • Subjects undergoing abdominoplasty have a relatively high incidence of opioid-based side effects. From an experimental standpoint, this is a positive because it provides an opportunity to demonstrate putative opioid-sparing properties of novel molecules.
  • There are several key design characteristics that are critical to the success of the model (intraoperative analgesia, specifics of the surgical procedure, provision of rescue drugs)
  • The model has certain weaknesses that must be understood when designing clinical programs
     
  • 14:00 CR845: A novel kappa opioid receptor agonist for acute post-operative pain, chronic pain of osteoarthritis and pruritus

    Joseph Stauffer

    Joseph Stauffer, Chief Medical Officer, Cara Therapeutics
    View Bio

  • Discussion of unique pharmacology of CR845
  • Analysis of respiratory safety and abuse liability when used for treatment of pain
  • Summary of up to date results from phase II osteoarthritis trials
  • Future hopes for CR845
     
  • 14:40 CNTX-6970 a novel CCR2 antagonist with a unique analgesic signature

    Randall Stevens

    Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.
    View Bio

  • Mechanism of action
  • Unique analgesic signature in preclinical models
  • Using Big Data to identify clinical development targets
  • Findings from Phase 1 clinical studies and next steps
     
  • 15:20 Afternoon Tea

    15:50 VM202, a DNA-based Potential Disease-Modifying Treatment for Painful Diabetic Neuropathy

    William Schmidt

    William Schmidt, Vice President, Clinical Development , Viromed
    View Bio

  • VM202 is a naked plasmid DNA vector engineered to express two isoforms of human hepatocyte growth factor (HGF).
  • In an ongoing Phase 3 clinical study, VM202 (8 mg/leg) or Placebo is administered i.m. to the calf muscle of each leg in a defined multi-injection pattern on Days 0 and 14 and again on Days 90 and 104.
  • Phase I/II and separate Phase 2 results show robust reductions in foot pain (p<0.05 vs. baseline) and a trend in improved sensory function through 9-12 months after initial treatment in subjects receiving VM202.
  • Pain relieving effects were more pronounced in patients who are not taking Lyrica (pregabalin) and/or Neurontin (gabapentin).
  • VM202 demonstrated an excellent safety profile in Phase I/II and Phase 2 clinical studies.
  • 16:30 Zilretta: Development of an extended release intra-articular therapeutic for osteoarthritis

    Toni Williamson

    Toni Williamson, Senior Director Non-Clinical Research, Flexion Therapeutics
    View Bio

  • Zilretta microsphere technology – how does it work?
  • The challenges of developing an extended release product
  • Summary of pre-clinical data
  • Summary of clinical studies
  • Case study examples
     
  • 17:10 Trial conduct in chronic pain conditions; Pitfalls and challenges

    Yanina Flossbach

    Yanina Flossbach, Associate Medical Director Neuroscience , Novartis Pharmaceuticals

  • Patient reported outcomes in clinical trials in pain
  • Reducing placebo responses
  • Patient recruitment challenges 
  • Data handling and management
  • Other considerations
     
  • 17:50 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Co-chairs' Opening Remarks

    Randall Stevens

    Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.
    View Bio

    Kerrie Brady

    Kerrie Brady, Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
    View Bio

    9:10 The TREK 1 agonists, a promising way to solve the opioid crisis?

    Jean Deregnaucourt

    Jean Deregnaucourt, Scientific Director, Innopain
    View Bio

  • An exemple of TREK 1 agonists: the substituted acrilyc acid derivatives
  • In vitro and in vivo pharmacological profile
  • Challenges and promises for the future
     
  • 9:50 Development of NMDA receptor modulators in central pain disorders

    Torsten Madsen

    Torsten Madsen, CMO, Aptinyx
    View Bio

  • The NMDA receptor is an attractive therapeutic target for neuropathic and chronic pain disorders
  • The preclinical development, data and pharmacology of NYX-2925 will be presented
  • The clinical development strategy for NYX-2925 will discussed
     
  • 10:30 Morning Coffee

    11:00 Selective TARP-dependent AMPA Receptor Antagonists as a Novel Therapy for Chronic Pain

    Eric Nisenbaum

    Eric Nisenbaum, Head of Neurophysiology, Eli Lilly & Co
    View Bio

  • The role of AMPA receptors in synaptic plasticity in pain pathways
  • Expression and functional consequences of Transmembrane AMPA receptor Regulatory Proteins (TARPs)
  • Identification of TARP-dependent AMPA receptor antagonists
  • Evidence for LY3130481 (CERC-611) as a novel analgesic
  • 11:40 Drugging the un-druggable: P2X4 mAbs as therapeutics for pain

    Iain Chessell

    Iain Chessell, VP & Head, IMED Neuroscience , AstraZeneca
    View Bio

  • Novel approaches to discovery of antibodies to P2X4
  • Functional and electrophysiological characterisation
  • Reaching the CNS – application of novel BBB technologies to access the spinal cord with antibody therapies
  • Efficacy in preclinical models and next steps
     
  • 12:20 Round table discussion session

  • Depression and chronic pain – Does constant pain cause depression or is depression a co-symptom of pain caused by intrinsic changes to neurons?

    Iain Chessell

  • Opioid drugs – Amid an opioid crisis, do abuse resistant drugs work and are we doing enough to reduce harm from opioids?

    Joseph Stauffer

  • What can the pain therapeutics industry expect with the ageing population?

    Randall Stevens

  • How should patient engagement be managed clinical trials for analgesic drugs to reduce the placebo effect and increase the success of clinical trials?

    Kerrie Brady

  • Why are novel analgesic targets so challenging to find and target effectively with drugs?

    Jenny Laird

  • Can stem cells ever replace animal models in preclinical studies? – Benefits and challenges.

    Theo Meert

  • Are the Guideline documents, and interactions from regulatory bodies, sufficient for the pain therapeutics industry?

    Invitation to host to : MHRA
     

  • Kerrie Brady

    Kerrie Brady, Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
    View Bio

    Randall Stevens

    Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.
    View Bio

    Joseph Stauffer

    Joseph Stauffer, Chief Medical Officer, Cara Therapeutics
    View Bio

    Iain Chessell

    Iain Chessell, VP & Head, IMED Neuroscience , AstraZeneca
    View Bio

    Theo Meert

    Theo Meert, Head of Global Government Grant Office, Janssen Pharmaceutical NV, J&J
    View Bio

    Jenny Laird

    Jenny Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    View Bio

    13:00 Networking Lunch

    14:00 Big Data for Big Decisions

    Kerrie Brady

    Kerrie Brady, Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
    View Bio

  • How to best develop a portfolio of novel non-opioid products for pain?
  • Integration of human expertise and artificial intelligence
  • Using metadata to qualify big data output
  • Can Big Data increase technical success for novel pain drug development?
     
  • 14:40 Development update on Erenumab

    Daniel Mikol

    Daniel Mikol, Executive Medicl Director Global Development Neuroscience, Amgen
    View Bio

  • The calcitonin gene-related peptide  (CGRP) pathway is pathophysiologically relevant in migraine
  • Erenumab is an investigational monoclonal antibody targeting the canonical receptor for CGRP
  • In episodic migraine prevention studies, erenumab has demonstrated efficacy in reducing migraine frequency and use of acute headache medications
  • In chronic migraine, erenumab has demonstrated efficacy in reducing migraine frequency and use of acute medications in patients with or without acute medication overuse
     
  • 15:20 Afternoon Tea

    15:50 New approaches to developing pain products

    Theo Meert

    Theo Meert, Head of Global Government Grant Office, Janssen Pharmaceutical NV, J&J
    View Bio

  • Search for proof of concept testing
  • Search for alternative development plans
  • New marketing/entry strategies needed?
     
  • 16:30 Case Study: NKTR-181- a novel approach to an old-school target

    Stephen Doberstein

    Stephen Doberstein , Senior Vice President, Research and Development and Chief R&D Officer, Nektar Therapeutics

  • Abuse liability of drugs is strongly related to their CNS pharmacokinetics
  • NKTR-181 is a first-in-class opioid analgesic with strategic brain entry kinetics
  • Limiting the rate of entry of mu-opioid agonists reduces their likeability
  • NKTR-181’s inherent long circulating half-life reduces withdrawal symptoms
  • Pivotal efficacy, safety, and abuse liability studies are completed
     
  • 17:10 An industry perspective from Grunenthal

    Mark Field

    Mark Field, SVP, Head Global Clinical Development , Grunenthal GmbH

  • Approaching pain as a disease – not just a symptom
  • Mapping the landscape of pain
  • Using a target-to-disease approach to identify novel compounds for development
     
  • 17:50 Co-chairs' Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Daniel Mikol

    Daniel Mikol

    Executive Medicl Director Global Development Neuroscience, Amgen
    Iain Chessell

    Iain Chessell

    VP & Head, IMED Neuroscience , AstraZeneca
    Joseph Stauffer

    Joseph Stauffer

    Chief Medical Officer, Cara Therapeutics
    Kerrie Brady

    Kerrie Brady

    Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
    Randall Stevens

    Randall Stevens

    Chief Medical Officer, Centrexion Therapeutics Corp.
    William Schmidt

    William Schmidt

    Vice President, Clinical Development , Viromed

    Alexander Oksche

    Executive Director , Mundipharma Research GmbH & Co. KG
    Alexander Oksche

    Alexander Oksche is Executive Director of Academic Alliances at Mundipharma Research GmbH & Co. KG focusing on R&D collaborations to advance scientific insights of internal drug development programmes. Alexander joined Mundipharma Research in 2006 to lead the internal R&D Innovation Process and later Pharmacological & Translational Science resulting in several drug development activities for the treatment of chronic pain. Alexander’s research areas cover classical and novel signalling pathways of G protein-coupled receptors and translational aspects of acute and chronic pain. He authored / co-author more than 40 peer-reviewed publications and of several book chapters. Alexander graduated as MD from Heinrich-Heine-University in Duesseldorf in 1992 and gained his PhD degree in Pharmacology and Toxicology from Charité Berlin in 2003. Since 2007 Alexander is lecturer in Pharmacology and has been appointed as Professor for Pharmacology at the Medical Faculty of the University Giessen in 2014.

    Daniel Mikol

    Executive Medicl Director Global Development Neuroscience, Amgen
    Daniel Mikol

    Daniel Mikol obtained his MD and PhD at the University of Chicago under Kari Stefansson, now deCODE CEO. He completed a Neurology residency at the University of California, San Francisco and fellowship at the University of Michigan. He continued to work on staff at the University of Michigan, an active clinician and clinical researcher, with interests in neuroimmunology. He left the University of Michigan in 2008 as Associate Professor, and since he has worked in global clinical development for several biotech companies, most recently joining Amgen in 2015 to lead the global development of erenumab (human anti-CGRP receptor mAb) for migraine prevention.

    Eric Nisenbaum

    Head of Neurophysiology, Eli Lilly & Co
    Eric Nisenbaum

    Dr. Nisenbaum received his B.S. in Psychology from Indiana University and his Ph.D. in Neuroscience from the University of Pittsburgh where his research focused on the relationship between changes in neurophysiological, neurochemical and behavioral indices in an animal model of Parkinson’s Disease. He subsequently went to the Department of Anatomy and Neurobiology at the University of Tennessee Health Science Center as a postdoctoral research associate and was granted Young Investigator Awards from the National Alliance for Research on Schizophrenia and Depression (NARSAD) and the Tourette Syndrome Association to study the roles of intrinsic ion channels and their modulation by neurotrasmitters in regulating the excitability of neostriatal neurons. In 1995, he received an NIH FIRST award and continued this research as an assistant professor in the Department of Psychology at the University of Connecticut. In 1998, Dr. Nisenbaum joined Eli Lilly where his research has focused on the biophysical mechanisms and functional consequences of allosteric regulation of ionotropic and metabotropic glutamate receptors and voltage-gated ion channels. He has led multiple cross-functional discovery efforts for glutamate receptor modulators as novel therapies for chronic pain, migraine, cognitive deficits in schizophrenia and neurodegeneration in Parkinson’s Disease. These efforts have contributed to the advancement of several promising drug candidates to the clinic.

    Gordon Munro

    Senior Scientist, Danish Headache Centre
    Gordon Munro

    Gordon Munro is a senior scientist at the Danish Headache Center in Copenhagen. A transition from academic research in opioids/neuroendocrinology into pain drug discovery started at NeuroSearch in 2001 and continued at Lundbeck, where pain activities focused primarily on developing modulators of ion channels as novel analgesics. A strong emphasis on animal pain models and behavioral pharmacology has contributed to the publication of 70 peer-reviewed articles, numerous patents and the clinical development of 4 pain-related compounds. He is also associated with the Danish biotech Hoba Therapeutics who are currently developing a novel neurotrophic protein for the treatment of neuropathic pain.

    Iain Chessell

    VP & Head, IMED Neuroscience , AstraZeneca
    Iain Chessell

    Dr. Iain Chessell is the Head of the Neuroscience Innovative medicines unit at AstraZeneca, based in Cambridge UK, leading a cross-functional team dedicated to discovery and clinical development of the neuroscience portfolio.Dr. Chessell joined the AstraZeneca (AZ) subsidiary, MedImmune, in November 2008 as vice president, Research, with the intent of initiating neuroscience R&D at MedImmune. After building a portfolio in analgesia and neurodegeneration, in 2010 he was promoted to vice president and head of the Neuroscience Center of Excellence (CoE) and subsequently head of the AstraZeneca neuroscience innovative medicines unit. Dr Chessell also serves on the AstraZeneca IMED leadership team which has responsibility for running the AZ’s discovery and early development organisation. Prior to joining AZ, Dr. Chessell was chief executive officer at NeuroDiscovery where he completed a number of Phase 1 and Phase 2 clinical programs for analgesia. Previously, he was global head of pain R&D for GlaxoSmithKline, where he delivered a portfolio of clinical candidates, and was involved in 19 clinical development projects from Phase 1 to Phase 3. He was also responsible for review of potential in-license opportunities, and was chair of the core disease teams for pain and neurodegeneration, as well as serving as chair of the Neurology management team. Dr. Chessell also managed several high profile academic and industrial collaborations, and is author of more than 95 peer reviewed publications. Dr. Chessell received his bachelor’s degree in pharmacology from University College London, and received his doctoral degree from the Department of Neurochemistry at the Institute of Neurology, London.

    Jean Deregnaucourt

    Scientific Director, Innopain
    Jean Deregnaucourt

    D V M, Thesis Prize Winner, Graduate in Pharmacology (Paris Medical Faculty), Post doctoral fellow at UCLA, was until recently Exec VP Bus Dev at Pasteur Institute after being CEO of the Medicen Paris Region Biocluster. His previous positions were VP Project Management, then VP Chemical and Pharm Dev at Rhone Poulenc Rorer (1990-1998) and later, President of the Pierre Fabre Laboratories R&D (1998-2003). He contributed to the international developments and worldwide registrations of a dozen of products among them two blockbusters, Clexane and Taxotere. Very recently, FDA approved Fetzimab an antidepressor, he patented a few years ago. Since 2016, Jean is now Chief Scientific Director at Innopain.

    Jenny Laird

    Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    Jenny Laird

    Jennifer Laird, Ph.D., D.Sc. is Senior Director, Search & Evaluation at Eli Lilly and Company, based at Lilly’s European Headquarters near London. The Search & Evaluation team complements Lilly’s internal R&D efforts by evaluating and in-licensing assets and technologies and by collaborating with external partners to advance molecules through discovery and development. Dr. Laird joined Lilly in 2012; prior to that, she spent 10 years at AstraZeneca as Executive Director heading the Translational Science department in Neuroscience and Project Director leading preclinical and early development projects. Dr. Laird received doctorates from Bristol University and University of Alicante, Spain, serves as an Editorial Board member of Neuropharmacology and European Journal of Pain and holds an honorary appointment as Profe

    Joanne Taylor

    VP, Head of Neuroscience, Prescient Healthcare Group
    Joanne Taylor

    Joanne, who has a PhD in developmental neuroscience from King’s College London, heads up Prescient’s neuroscience business. After completing a postdoctoral fellowship, she joined Eisai. Over her 18-year career there, she led global teams in the discovery of novel therapeutic strategies for neurological conditions. As Director of Strategic Research Planning, she led reviews of Eisai’s neuroscience portfolio to identify areas of major focus and investment. Since joining Prescient in 2011, Joanne has supported portfolio, clinical, regulatory and commercial strategies for a wide array of clients. She is a seasoned workshop moderator.

    Joseph Stauffer

    Chief Medical Officer, Cara Therapeutics
    Joseph Stauffer

    As well as his position at Cara Therapeutics, Joe is also the Founder of Alta Life Sciences, LLC, a boutique pharmaceutical/investment consulting firm. He is a 2002 founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT). In 2011, under the FDA’s Critical Path Initiative, this collaboration became an official public-private partnership between pharma, FDA, NIH, academia and patient advocacy associations. In 2005 he served as an expert member of the FDA/Mayo Clinic Working group on Patient Reported Outcomes and co-authored the supportive paper (Value in Health, Nov/Dec 2007) on validation of self-reported outcome measures.
    In 2007 he was named one of the “100 Most Inspiring People” by PharmaVOICE magazine. In 2011 he was selected as a Board member of the American Academy of Pain Medicine Foundation. In 2014 he was appointed to the Board of Directors of TrialScope, a provider of technology enhanced clinical trial solutions and services.
     

    Kerrie Brady

    Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
    Kerrie Brady

    Kerrie Brady is a founder and chief business officer of Centrexion Therapeutics. Kerrie’s career includes 30 years of experience as an international pharmaceutical executive working in both big pharma and biotech companies. Prior to joining Centrexion, Kerrie was the chief operations officer for Vallinex Inc., a company she founded as a spin out from Arcion Therapeutics, Inc., a biotech company developing topical products for the treatment of neuropathic pain. Kerrie was also the co-founder and chief operations officer for Arcion Therapeutics Inc. Previously, she was the founder, president and chief executive officer of Traxion Therapeutics, Inc., a biotech company focused on the development of new drugs to treat intractable pain. Prior to starting on the entrepreneurial path Kerrie’s experience spanned business development (KMG Japan, Entremed, Intracel), business operations (CMC for Biopharmaceutical Research), marketing and regulatory affairs (Rhone Poulenc) Kerrie holds a BPharm from Victorian College of Pharmacy, an MBA from the University of Melbourne and an M.S. in biopharmaceuticals from the University of New South Wales. In 2016, Kerrie was named to the PharmaVOICE100 Most Inspiring People for her contributions to the life-sciences industry.

    Lisa Broad

    Senior Research Advisor , Eli Lilly and Company
    Lisa Broad

    Lisa Broad, Ph.D. is a Senior Research Advisor within the Neuroscience division at Eli Lilly and Company, based at Lilly’s European Headquarters near London. Dr. Broad heads up a pre-clinical Neurophysiology group working on Pain/Migraine and Neurodegeneration. Prior to joining Lilly in 2000, Dr. Broad completed post-doctoral studies at the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA and the University of Cambridge. Dr. Broad received her doctorate from the University of Cambridge in 1997.

    Mark Field

    SVP, Head Global Clinical Development , Grunenthal GmbH
    Mark Field

    Neil Singla

    Founder & Chief Scientific Officer, Lotus Clinical Research, Llc
    Neil Singla

    Neil Singla, MD, Founder & Chief Scientific Officer, Lotus Clinical Research, LLC - Dr. Neil Singla is a nationally recognized key opinion leader in analgesic protocol design and implementation. He has published extensively and is a frequent lecturer for physicians, pharmaceutical companies and medical research institutes throughout the country. For the past several years, the main focus of Dr. Singla's academic endeavors has been to analyze and understand how the inherent variability in subjective endpoint clinical trials can be minimized. He has developed novel techniques for patient education designed to minimize variability, reduce placebo response and increase effect size. Dr. Singla also serves as Chairman of the Clinical Trials Special Interest Group at both the American Pain Society and the International Association for the Study of Pain.

    Randall Stevens

    Chief Medical Officer, Centrexion Therapeutics Corp.
    Randall Stevens

    Randall Stevens, M.D. joined Centrexion Therapeutics as the Chief Medical Officer in April 2015. Randall is a board certified internist and rheumatologist with more than 25 years in pharmaceutical medicine. Prior to joining Centrexion, he served as the Corporate Vice President, Head of Inflammation and Immunology Clinical Development of Celgene Corporation. Earlier in his career, Randall spent 11 years at F. Hoffmann La Roche where he was a global leader in inflammation and immunology clinical research. In total, Randall has played an integral role in bringing five drugs to market. Additionally, he is Clinical Professor of Medicine at Robert Wood Johnson School of Medicine and on the faculty since 1987.

    Simon Ruini

    Director, phd pharma design
    Simon Ruini

    Simon Ruini is Managing Director of Pharma Design Limited, a boutique service provider for the biotech and pharmaceutical industry. Simon is a well-qualified professional with broad experience in Regulatory, Safety and Clinical Development in the pharma and biotech. He specializes in Marketing Authorisation filings in EU and Clinical Study design. Simon is a visiting lecturer at UNIGE in Geneva and ETH in Zurich. During his consulting career Simon has provided advice and work for Roche-Genentech, Eli Lilly, Sanofi, Novartis, Norgine, Mitsubishi Tanabe, Alliance Unichem.

    Stephen Doberstein

    Senior Vice President, Research and Development and Chief R&D Officer, Nektar Therapeutics
    Stephen Doberstein

    Theo Meert

    Head of Global Government Grant Office, Janssen Pharmaceutical NV, J&J
    Theo Meert

    Prof Theo F. Meert is head of the R&D Global Government Grant office (G3O) of J&J. He is also a professor and scientific advisor/researcher at different universities: Leuven, Antwerp, Brussels, Hasselt and Ghent.
    During his career at J&J that started in 1981, Dr. Meert has been appointed to multiple international global functions. Within his various functions, he guided different multidisciplinary research teams in the field of CNS (Psychiatry - Addiction - Pain -Neurology/ Alzheimer). The activities of these groups covered the complete drug discovery process from early drug candidate selection to POC and further clinical testing. He was a key driver for several advanced projects in the CNS area leading to marketed drugs. Dr. Meert also supports some Full Development products and is involved in the scientific support of novel and marketed products. Dr. Meert has constructed an extensive network within J&J and external scientific and clinical organizations. He has also built an external network of external partnership initiatives and was instrumental in various novel external innovation models.

    Dr. Meert’s scientific expertise is reflected in multiple patents (>15), publications (> 243), congress communications (> 200) and invited lectures (>190). Dr. Meert obtained a Ph.D. in psychopharmacology in Experimental Psychology at the University of Brussels (1986) and a Ph.D. in Medicine/Anesthesiology at the University of Antwerp (1994).
     

    Toni Williamson

    Senior Director Non-Clinical Research, Flexion Therapeutics
    Toni Williamson

    Toni Williamson joined Flexion Therapeutics as Senior Director of Non-Clinical Research in 2015. Prior to joining Flexion, Toni spent 10 years at Amgen, initially managing the Alzheimer’s disease in vivo pharmacology group and leading small molecule drug discovery teams. She then moved into Toxicology, supporting projects from early discovery to clinical development, predominantly in the Neuroscience Therapeutic Area. Prior to joining Amgen, Toni led the Alzheimer’s disease in vivo biochemistry group at Merck, Sharpe and Dohme, and prior to Merck, she was Head of Biological Models at Trophos, a start-up company focused on neurodegenerative diseases. Toni received her bachelor’s degree in Biochemistry & Physiology from the University of Reading, and her PhD from King’s College London. Toni did her post-doctoral research in Dr. Don Cleveland’s laboratory (UCSD).

    Torsten Madsen

    CMO, Aptinyx
    Torsten Madsen

    Dr Torsten Madsen holds and MD and a Ph.D. in neuroscience, both from Copenhagen University. He did clinical training in medicine and psychiatry at Danish University hospitals, and pursued basic research as a postdoc at laboratory for Molecular Psychiatry at Yale. After he joined Lundbeck, he oversaw the development of early and late phase drugs across all phases of development, through to approval. At Aptinyx, he is responsible for clinical development of a portfolio of NMDA receptor modulators.

    William Schmidt

    Vice President, Clinical Development , Viromed
    William Schmidt

    Dr. Schmidt has more than 30 years of experience in pain medicine pharmaceutical development. He is President of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs to pharma and biotech companies worldwide, and simultaneously part-time VP of Clinical Development for ViroMed Co., Ltd. (Seoul, South Korea). In previous assignments, Dr. Schmidt was a key member of teams leading to the development and regulatory approval of Entereg® (alvimopan), a peripherally-acting opioid antagonist, Acelex® (polmacoxib), a dual-acting COX-2 and carbonic anhydrase inhibitor, nalbuphine (Nubain®), naltrexone (ReVia®) and the oxycodone-ibuprofen formulation used in Combunox™. Dr. Schmidt received his Ph.D. in Pharmacology from the University of California, San Francisco.

    Yanina Flossbach

    Associate Medical Director Neuroscience , Novartis Pharmaceuticals
    Yanina Flossbach

    Sponsors and Exhibitors

    Official Media Partner

    Official Publication

    Online Partner

    Supporters

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    WELCOME LETTER FROM THE CHAIRS

    Download

    Sponsors and Exhibitors


    Lotus Clinical Research

    Sponsors and Exhibitors
    http://www.LotusCR.com

    Lotus Clinical Research is a specialty analgesic CRO, research site, and regulatory consulting firm supporting all phases of discovery for analgesic treatments, focused on improving the scientific accuracy of analgesic programs. Led by Dr. Neil Singla, Lotus focuses on optimizing design/conduct of clinical trials in pain, providing scientific leadership at every step of the development process.

    Media Partners


    ACNR

    Official Media Partner
    http://www.acnr.co.uk

    ACNR (Advances in Clinical Neuroscience & Rehabilitation) is one of the most widely read publications in the neurology field in the UK. It provides concise review articles, specialist reviews of core papers from international journals, conference news, book reviews, short accounts of best management practice, case reports, news of awards/appointments and more. This independently produced journal is available free of charge to members of the profession, and we welcome your input.


    Pain News

    Official Media Partner
    https://www.britishpainsociety.org/pain-news-1/

    The British Pain Society Newsletter Pain News is published quarterly and is edited by Dr Arasu Rayen. Members of the Society will receive a free copy and are encouraged to contribute to the content.

    Media Partners


    The British Journal of Pain

    Official Publication
    http://bjp.sagepub.com/

    The British Journal of Pain is the official journal of the British Pain Society. It provides scientists and clinicians in pain medicine with peer-reviewed review articles and expert opinions on all aspects of pain management from basic science to its clinical application including pain physiology, pharmacology and interventions. This journal provides content of multidisciplinary interest and reviews and forecasts important issues and trends in the management of acute and chronic pain.

    Media Partners


    Centre for Human Drug Research

    Online Partner
    http://www.chdr.nl/

    Since 1987, CHDR has developed into a unique research organisation specialising in early phase studies which combines knowledge and academic collaborations with operational excellence in clinical trial services. CHDR's strong track record in analgesic and pain research allows us to offer an efficient route towards proof of concept in patients.

    Media Partners


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Copybook - Pharmaceutical

    Supporters
    http://www.copybook.com/pharmaceutical

    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    EIN Presswire

    Supporters
    http://www.einpresswire.com/free

    EIN Presswire has a distribution "foot-print" that includes millions of users of our EIN Newsdesk media monitoring services. We also maintain one of the world's leading media directories providing us with up-to-date contacts for media in every country and U.S. state. Further distribution is achieved via RSS, email, partner websites, and social media. We are both a destination (EIN Newsdesk) and a distributor (EIN Presswire) for news. In one place you can distribute your news to the targeted audiences you select and monitor news on that topic published by thousands of worldwide sources. For more information or to try us FREE, please visit www.einpresswire.com/free


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    European Biotechnology Network

    Supporters
    http://european-biotechnology.net/

    The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Samedan

    Supporters
    http://www.samedanltd.com/magazine/13.

    International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Labiotech.eu

    Supporters
    http://labiotech.eu

    Labiotech.eu is the leading digital media covering the European Biotech industry. It is used by over 55000 people monthly to keep a watch on the business and innovations of biotechnologies.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.